These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 24353180

  • 1. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
    Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, Taranova A, Abdul-Ghani M, DeFronzo RA.
    Diabetes; 2014 Aug; 63(8):2812-20. PubMed ID: 24353180
    [Abstract] [Full Text] [Related]

  • 2. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
    Liang H, Tantiwong P, Sriwijitkamol A, Shanmugasundaram K, Mohan S, Espinoza S, Defronzo RA, Dubé JJ, Musi N.
    J Physiol; 2013 Jun 01; 591(11):2897-909. PubMed ID: 23529132
    [Abstract] [Full Text] [Related]

  • 3. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep 01; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 4. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov 01; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 5. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
    Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2007 Jun 01; 292(6):E1775-81. PubMed ID: 17299078
    [Abstract] [Full Text] [Related]

  • 6. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.
    Diabetes; 1999 Sep 01; 48(9):1836-41. PubMed ID: 10480616
    [Abstract] [Full Text] [Related]

  • 7. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans.
    Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D.
    Am J Physiol Endocrinol Metab; 2009 Apr 01; 296(4):E758-64. PubMed ID: 19190263
    [Abstract] [Full Text] [Related]

  • 8. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA.
    Gastroenterology; 2007 Aug 01; 133(2):496-506. PubMed ID: 17681171
    [Abstract] [Full Text] [Related]

  • 9. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA.
    J Clin Endocrinol Metab; 2016 Mar 01; 101(3):1249-56. PubMed ID: 26765576
    [Abstract] [Full Text] [Related]

  • 10. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H, Stanley TL, Suresh C, De Sousa-Coelho AL, Frontera WR, Syu S, Braun LR, Looby SE, Feldpausch MN, Torriani M, Lee H, Patti ME, Grinspoon SK.
    J Clin Endocrinol Metab; 2016 Mar 01; 101(3):1123-33. PubMed ID: 26691888
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin.
    Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA.
    Acta Diabetol; 2008 Sep 01; 45(3):147-50. PubMed ID: 18357404
    [Abstract] [Full Text] [Related]

  • 15. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar 01; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 16. Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus.
    Saloranta C, Franssila-Kallunki A, Ekstrand A, Taskinen MR, Groop L.
    Diabetologia; 1991 Jun 01; 34(6):409-15. PubMed ID: 1884899
    [Abstract] [Full Text] [Related]

  • 17. Free fatty acids increase hepatic glycogen content in obese males.
    Allick G, Sprangers F, Weverling GJ, Ackermans MT, Meijer AJ, Romijn JA, Endert E, Bisschop PH, Sauerwein HP.
    Metabolism; 2004 Jul 01; 53(7):886-93. PubMed ID: 15254882
    [Abstract] [Full Text] [Related]

  • 18. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec 01; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    J Clin Endocrinol Metab; 2001 Dec 01; 86(12):5813-8. PubMed ID: 11739444
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.
    Lim EL, Hollingsworth KG, Smith FE, Thelwall PE, Taylor R.
    Clin Sci (Lond); 2011 Aug 01; 121(4):169-77. PubMed ID: 21388348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.